Introducing the new NDEWS Coordinating Center at UF
The National Drug Early Warning System (NDEWS), funded to the University of Florida by NIDA as of April 2020, aims to provide the field with the most timely, salient, and valuable information on emerging substance use trends.
About nDEWS
ABOUT OUR
Coordinating Center
NDEWS is led by scientists from the University of Florida, New York University, and Florida Atlantic University. Our Coordinating Center (CC) draws heavily on established and emerging public health surveillance methods and integrates expertise from multiple disciplines.
ABOUT OUR
Early Warning Network
Our Early Warning Network is comprised of scientists from 18 urban, suburban, and rural areas in the US. They will regularly collect community-level indicators of drug use, morbidity, and mortality.
ABOUT OUR
Scientific Advisory Group
Our Scientific Advisory Group is composed of 12 scientists from across the US and 5 experts from relevant government agencies to advise NDEWS leadership on relevant indicators, data harmonization, and interpretation.
NOVEL SURVEILLANCE
NEW TO NDEWS
Using novel surveillance to detect emerging drug trends
One aim of the new NDEWS is to incorporate and leverage novel surveillance methods to ensure early detection of signals of new and emerging drug trends, including data from "drug checking," an ongoing national venue-intercept study, our new Virtual HealthStreet, and the development of an innovative machine learning approach to detect emergence of new psychoactive substances in real-time through algorithms deployed to darknet drug markets and forums.
NDEWS COVID-19 Response
COVID-19
Assessing the impact of the COVID-19 pandemic on drug overdoses and services utilization
NDEWS is conducting ongoing interviews with three key informant groups to understand the impact of COVID-19 on people who use drugs across all 18 Early Warning Network sites: emergency responders, workers at syringe exchange programs, and funeral directors. Findings will be rapidly disseminated to the scientific community and public.
RECENT NEWS
Eutylone intoxications: an emerging synthetic…
NDEWS Co-Investigator Dr. Bruce Goldberger and NDEWS Scientific Advisory Group Member Dr. Barry Logan, along with other collaborators at NMS Labs and…
New psychoactive substances and drug monitoring…
NDEWS Principal Investigator Dr. Linda B. Cottler, co-editor of Addictive Disorders for Current Opinion in Psychiatry, invited articles in the July…
An old, dangerous drug has made a comeback with a…
NDEWS Co-Investigator Dr. Joseph Palamar discusses the re-emergence of gamma-hydroxybutyric acid (GHB) with NBC News in a new article.
Nora’s Blog: NIDA researchers adapt their…
Dr. Nora Volkow, the Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health, describes the NDEWS COVID-19…
